|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Ortho_Pharmaceutical
gptkb:Centocor
2000
2011
2014
2016
2018
|
|
gptkbp:clinicalTrials
|
gptkb:COVID-19_vaccine
HIV treatment
schizophrenia treatment
Crohn's disease treatment
multiple myeloma treatment
|
|
gptkbp:employeeCount
|
over 40,000
|
|
gptkbp:founded
|
1953
|
|
gptkbp:founder
|
gptkb:Paul_Janssen
|
|
gptkbp:globalPresence
|
over 150 countries
|
|
gptkbp:headquarters
|
gptkb:Beerse,_Belgium
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Janssen Pharmaceutica
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:notableFeature
|
gptkb:Xarelto
gptkb:Invega
Ticagrelor
Risperidone
Adalimumab
Canagliflozin
Daratumumab
Symtuza
Simeprevir
Ustekinumab
|
|
gptkbp:parentCompany
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:partnerships
|
gptkb:Global_Fund
gptkb:World_Health_Organization
gptkb:Gavi,_the_Vaccine_Alliance
|
|
gptkbp:products
|
antibiotics
antipsychotics
oncology drugs
|
|
gptkbp:researchFocus
|
neuroscience
cardiovascular diseases
infectious diseases
immunology
|
|
gptkbp:subsidiary
|
gptkb:Janssen_Biotech
gptkb:Janssen_Pharmaceuticals
gptkb:Janssen_Research_&_Development
|
|
gptkbp:website
|
www.janssen.com
|